Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 12/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 12/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1144297 | 1.00 | MGAM (0.42) | MGAMGAASIMGAM2MTNR1A | |
| SCHEMBL1144274 | 1.00 | MGAM (0.42) | MGAMGAASIMGAM2MTNR1A | |
| SCHEMBL5808284 | 0.83 | TSHR (0.41) | MTNR1AMTNR1BTSHRACACBALDH1A1 | |
| SCHEMBL16367683 | 0.82 | TSHR (0.40) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL12164763 | 0.82 | TSHR (0.40) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL8972302 | 0.82 | TSHR (0.40) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL22246440 | 0.81 | MGAM (0.48) | MGAMGAASIMGAM2MTNR1A | |
| SCHEMBL1405629 | 0.81 | MGAM (0.48) | MGAMGAASIMGAM2MTNR1A | |
| SCHEMBL13356642 | 0.81 | MGAM (0.48) | MGAMGAASIMGAM2MTNR1A | |
| SCHEMBL17208359 | 0.80 | TSHR (0.39) | MGAMGAASIMGAM2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4215530-A1 | ISOXAZOLINE COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS | FMC Corporation (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20230142248-A1 | METHOD FOR RACEMIC PREPARATION OF CHIRAL B-AMINO ACIDS AND DERIVATIVES THEREOF | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230142248-A1 | METHOD FOR RACEMIC PREPARATION OF CHIRAL B-AMINO ACIDS AND DERIVATIVES THEREOF | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20150344485-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-20150344485-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-20150344485-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| EP-2948456-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2015-12-02 | — | — | EP | disclosed |
| EP-1386901-B1 | Method for producing an optically active beta-amino acid | TAKASAGO PERFUMERY CO LTD (JP) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014114249-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014114249-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-07-31 | — | — | WO | disclosed |
| US-7893296-B2 | Method for producing an optically active β-amino acid | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-02-22 | — | — | US | disclosed |
| US-7763739-B2 | bidentante optionally N-containing P-ligands embracing a two-ring-system; for transition metal complexes to be used as catalysts | Evonik Degussa, GmbH (DE) | 2010-07-27 | — | — | US | disclosed |
| US-7763739-B2 | bidentante optionally N-containing P-ligands embracing a two-ring-system; for transition metal complexes to be used as catalysts | Evonik Degussa, GmbH (DE) | 2010-07-27 | — | — | US | disclosed |
| CN-101328134-A | Method for splitting 3-acetamido methyl butyrate antipode | BAOSHAN IRON & STEEL (CN) | 2008-12-24 | — | — | CN | disclosed |
| US-20080306264-A1 | bidentante optionally N-containing P-ligands embracing a two-ring-system; for transition metal complexes to be used as catalysts | DEGUSSA AG (DE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306264-A1 | bidentante optionally N-containing P-ligands embracing a two-ring-system; for transition metal complexes to be used as catalysts | DEGUSSA AG (DE) | 2008-12-11 | — | — | US | disclosed |
| US-20060122418-A1 | Method for producing an optically active beta-amino acid | MATSUMURA KAZUHIKO | 2006-06-08 | — | — | US | disclosed |
| US-7015348-B2 | Method for producing an optically active β-amino acid | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2006-03-21 | — | — | US | disclosed |
| US-20040023344-A1 | Method for producing an optically activ beta-amino acid | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-02-05 | — | — | US | disclosed |
| EP-1386901-A1 | Method for producing an optically active beta-amino acid | Takasago International Corporation (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306264-A1 | bidentante optionally N-containing P-ligands embracing a two-ring-system; for transition metal complexes to be used as catalysts | CCNE2, NDUFS2, SOD1 | MGAM 2511/4885GAA 3386/4885SI 4432/4885 |
| US-20150344485-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | PLA2G4A, PLA2G7, PLA2G6 | MGAM 2603/4885GAA 454/4885SI 3155/4885 |
| US-20060122418-A1 | Method for producing an optically active beta-amino acid | AADAT, DAO, BCAT2 | MGAM 128/4885GAA 191/4885SI 98/4885 |
| US-20230142248-A1 | METHOD FOR RACEMIC PREPARATION OF CHIRAL B-AMINO ACIDS AND DERIVATIVES THEREOF | GLP1R, SRR, GIPR | MGAM 374/4885GAA 1771/4885SI 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.